BRAIN-TARGETED NANO-DRUG DELIVERY FOR THE TREATMENT OF PARKINSON'S DISEASE

Abstract

Parkinson’s Disease affects 2% to 3% of overall individuals aged 65 years or older worldwide and is considered to be the second most common age-related neurodegenerative disease. Neuropathologic features of Parkinson’s Disease attributes to a loss of pigmented dopaminergic neurons in the substantia nigra and the formation of Lewy Bodies, as a result of intracellular accumulation of α-synuclein proteins. To our current day, only a few therapeutic approaches are considered promising, one of which is the Nanoscale approach. It gives an advantage over conventional approaches by offering solutions to complications that occur in the current treatment methods used for Parkinson’s Disease, namely by encapsulating and protecting the drug from extracellular degradations, allowing for a more sustained, efficient, and targeted drug release profile, thus reducing the risk of adverse effects of the drug used. In this study, we review, discuss, and briefly explain the nanoscale approaches, alternative administration routes, and studies conducted in vivo and in vitro for an efficient treatment and an alternative approach to Parkinson’s Disease.